首页|SLeX和CK19在甲状腺乳头状癌表达的临床病理意义

SLeX和CK19在甲状腺乳头状癌表达的临床病理意义

扫码查看
目的 探讨SLeX和CK19在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)表达的临床病理意义。方法 采用免疫组织化学EliVisionTM plus两步法检测SLeX和CK19在120例PTC组织及30例癌旁甲状腺组织中的表达,运用SPSS 22。0分析SLeX和CK19与患者年龄、TI-RADS分类、TNM分期、癌浸润、淋巴结转移(lymph node metastasis,LNM)5项临床病理指标的关系。结果 PTC和癌旁甲状腺组织SLeX阳性率分别为 67。5%(81/120)和 6。7%(2/30),CK19 阳性率分别为 87。5%(105/120)和 10。0%(3/30),差异均有统计学意义(P<0。05)。年龄<45岁组与≥45岁组,SLeX阳性率分别为63。2%(48/76)、75。0%(33/44),CK19阳性率分别为88。2%(67/76)、86。4%(38/44),组间差异均无统计学意义(P>0。05)。TI-RADS(4类+5类)组与6类组,SLeX阳性率分别为62。1%(59/95)、88。0%(22/25),组间差异有统计学意义(P<0。05),CK19阳性率分别为85。3%(81/95)、96。0%(24/25),组间差异无统计学意义(P>0。05)。TNM(T1 期+T2 期)组与 T3 期组,SLeX 阳性率分别为 58。2%(46/79)、85。4%(35/41),CK19阳性率分别为82。3%(65/79)、97。6%(40/41);有癌浸润组与无癌浸润组,SLeX阳性率分别为79。2%(57/72)、50。0%(24/48),CK19 阳性率分别为 94。4%(68/72)、77。1%(37/48);有 LNM 组与无 LNM 组,SLeX 阳性率分别为 79。4%(54/68)、51。9%(27/52),CK19 阳性率分别为 95。6%(65/68)、76。9%(40/52),上述3组组间比较差异均有统计学意义(P<0。05)。SLeX和CK19在120例PTC中共阳率为65。8%(79/120),共阴率为10。8%(13/120),两者表达呈正相关(r=0。40,P<0。05)。结论 SLeX和CK19高表达预示PTC分期晚,浸润性强,易发生LNM。
Clinicopathologic Significance of Expression of SLeX and CK19 in Papillary Thyroid Carcinoma
Objective To investigate the clinicopathologic significance of SLeX and CK19 expression in papillary thyroid carcinoma(PTC).Methods Immunohistochemical Eli VisionTM plus two-step method was used to detect the expression of SLeX and CK19 in 120 pieces of primary PTC tissue who underwent resection and 30 pieces of adjacent carcinoma tissue.The relationship between the expression of SLeX and CK19 and the clinicopathological parameters including patient age,TI-RADS classification,TNM stag-ing,carcinomatous infiltration,lymph node metastasis(LNM)were analyzed by SPSS 22.0.Results In pieces of primary PTC tissue and pieces of adjacent carcinoma tissue,the positive rates of SLeX were 67.5%(81/120)and 6.7%(2/30),CK19 were 87.5%(105/120)and 10.0%(3/30),respectively,with statistically significant differences(P<0.05).In the groups with patients aged<45 years versus 45 years,the SLeX positive rates were 63.2%(48/76)and 75.0%(33/44),and the CK19 positive rates were 88.2%(67/76)and 86.4%(38/44),respectively,with no statistically significant differences between the two groups(P>0.05).In the groups of TI-RADS(class 4 and 5)versus class 6,the SLeX positive rates were 62.1%(59/95)and 88.0%(22/25),respectively,and the differences between the two groups were statistically significant(P<0.05).The CK19 positive rates were 85.3%(81/95)and 96.0%(24/25),respectively,with no statistically significant differences between the two groups(P>0.05).In the groups of TNM(stage T1 and T2)versus stage T3,the SLeX positive rates were 58.2%(46/79)and 85.4%(35/41),and the CK19 positive rates were 82.3%(65/79)and 97.6%(40/41),respectively.In the groups with versus without carcinomatous infiltration,the SLeX positive rates were 79.2%(57/72)and 50.0%(24/48),and the CK19 positive rates were 94.4%(68/72)and 77.1%(37/48),respectively.In the groups with versus without LNM,the SLeX positive rates were 79.4%(54/68)and 51.9%(27/52),and the CK19 positive rates were 95.6%(65/68)and 76.9%(40/52),respectively,and the differences between the three above groups were statistically significant(P<0.05).The copositive and conegative expression rates of SLeX and CK19 in 120 pieces of primary PTC tissue were 65.8%(79/120)and 10.8%(13/120),respectively,with a positive correlation(r=0.40,P<0.05).Conclusion High expression of SLeX and CK19 in PTC may predict late tumor stage,more aggressive in-vasion and being more prone to LNM.

Papillary thyroid carcinomaSLeXCK19Tumor invasionLymph node metastasisImmunohistochemistry

韩昭、聂阿娜、万立、胡玮、陈晓丽、李伟、尚培中、李晓武

展开 >

中国人民解放军陆军第八十一集团军医院普通外科,河北 张家口 075000

张家口市第一医院 麻醉科,河北 张家口 075000

中国人民解放军陆军第八十一集团军医院检验病理科,河北 张家口 075000

甲状腺乳头状癌 SLeX CK19 肿瘤浸润 淋巴结转移 免疫组织化学

2025

河北北方学院学报(自然科学版)
河北北方学院

河北北方学院学报(自然科学版)

影响因子:0.348
ISSN:1673-1492
年,卷(期):2025.41(2)